Growth Metrics

Krystal Biotech (KRYS) Income towards Parent Company: 2021-2025

Historic Income towards Parent Company for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.4 million.

  • Krystal Biotech's Income towards Parent Company rose 192.12% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 279.88%. This contributed to the annual value of $89.2 million for FY2024, which is 715.58% up from last year.
  • Per Krystal Biotech's latest filing, its Income towards Parent Company stood at $79.4 million for Q3 2025, which was up 107.05% from $38.3 million recorded in Q2 2025.
  • Krystal Biotech's Income towards Parent Company's 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of -$50.0 million in Q1 2022.
  • Over the past 3 years, Krystal Biotech's median Income towards Parent Company value was $27.2 million (recorded in 2024), while the average stood at $21.9 million.
  • As far as peak fluctuations go, Krystal Biotech's Income towards Parent Company plummeted by 215.99% in 2022, and later surged by 3,730.15% in 2025.
  • Krystal Biotech's Income towards Parent Company (Quarterly) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then soared by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then spiked by 192.12% to $79.4 million in 2025.
  • Its last three reported values are $79.4 million in Q3 2025, $38.3 million for Q2 2025, and $35.7 million during Q1 2025.